Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

Risk Factors and Trends in Melanoma

August 27, 2014
Publication
Article
Targeted Therapies: MelanomaMelanoma (May 2014)
Volume 3
Issue 1

Risk factors for contracting melanoma are complex and can include environmental exposure and an individual’s genetic susceptibility, but people at highest risk are those with a personal or family history of melanoma and those with large, atypical, and/or multiple (more than 50) nevi.

Risk factors for contracting melanoma are complex and can include environmental exposure and an individual’s genetic susceptibility,1,2but people at highest risk are those with a personal or family history of melanoma and those with large, atypical, and/or multiple (more than 50) nevi.

“The people at greatest risk to develop melanoma epidemiologically are those with fair skin, light or red hair, light eyes, and extensive history of sun exposure or previous sunburn,” said Christopher J. Miller, MD, director of dermatologic surgery at the Hospital of the University of Pennsylvania. “All of these people should be monitored very closely,” he cautioned.

Other risk factors include a tendency to freckle, sun sensitivity, use of tanning booths, and immunosuppression. The genetic susceptibility and environmental exposure risks are most prominently illustrated in individuals with fair skin and light eyes; however, melanoma can occur in any ethnic group and in areas of the body that have not had substantial sun exposure.1,2

Individuals with few nevi tend to develop melanoma on areas of the body that are repeatedly exposed to sun, while individuals with large numbers of nevi have an increased risk of melanoma where nevi tend to be present, regardless of sun exposure (eg, the back).2

According to Miller, both total cumulative ultraviolet (UV) exposure and intensity of individual exposures play a role in etiology and subtype of melanoma.

“Intermittent, intensive sun exposure is a significant risk factor to develop the most common type of melanoma, called superficial spreading melanoma,” Miller said. This type of melanoma is typically found on areas of the body that do not receive constant and continued UV exposure (eg, the trunk). “There is another subtype of melanoma called a lentigo maligna melanoma that occurs more commonly on the head and neck or on the dorsal hands and forearms—areas that are more commonly exposed to regular, cumulative sun exposure,” Miller explained.

The increasing incidence of melanoma appears consistent throughout the world, but varies when comparisons in latitude are noted. Melanoma is very rare in Africa, whereas Australia has among the highest incidence rates of melanoma worldwide.3

Approximately 76,100 new cases of melanoma will be diagnosed in the United States in 2014.2Although melanoma accounts for less than 2% of skin cancer cases, it is responsible for most skin cancer deaths. An estimated 9710 persons will die from melanoma in 2014.2

The median age at diagnosis of melanoma is 59 years.1Although the risk of melanoma increases with age, it is one of the most common cancers diagnosed in young adults, particularly young females.1,2 Melanoma is slightly more common in men than in women (1.2:1). Incidence of melanoma is higher in women before the age of 45 years, but rates in men are more than double and triple those in women by (“Risk Factors and Trends” continued) the ages of 60 and 80 years, respectively.1,2

The incidence of melanoma also varies by race; it is approximately 20-fold higher among whites than among African Americans. Incidence rates of melanoma among whites increased by 2.7% per year from 2006 to 2010. Melanoma is rare in African Americans, with a lifetime risk of 0.1%, compared with a lifetime risk of 2.4% among whites. Whites also have a significantly higher incidence compared with Asians and Hispanics. Although incidence of melanoma is lower in the Hispanic and black populations, these groups are more likely to have metastatic disease and poorer outcomes.1,2

The clinical outcome of melanoma initially depends on stage at diagnosis. About 82% to 85% of patients with melanoma present with localized disease, 10% to 13% present with regional disease, and the remaining 2% to 5% have distant metastatic disease at the time of diagnosis.1,2

The 5-year relative survival rate for melanoma, regardless of stage at diagnosis, is 91%. When diagnosed at a local stage, the survival rate is 98%; but metastasis beyond the local site is associated with significantly reduced relative survival (62% and 16% for regional and distant metastases, respectively).1,2Five-year survival rates for melanoma have increased from 82% in the mid-1970s to 88% during the late 1980s and to 93% in 2009. However, survival rates remain substantially lower for African Americans, despite an increase in survival from 57% several decades ago to 77% in 2009 in this population.2

Trends in mortality from melanoma are associated with age. In recent years, death rates from melanoma have been rapidly declining in whites younger than 50 years; however, among whites 50 years and older, melanoma death rates increased by 1.1% per year in men and 0.2% per year in women during the same period.1,2

References

  1. National Comprehensive Cancer Network. Melanoma (Version 3.2014). http://www.nccn.org/professionals/physician_ gls/pdf/melanoma.pdf. Accessed February 20, 2014.
  2. American Cancer Society. Cancer Facts & Figures 2014. http:// www.cancer.org/acs/groups/content/@research/documents/ document/acspc-041770.pdf. Accessed February 20, 2014.
  3. Erdei E, Torres SM. A new understanding in the epidemiology of melanoma.Expert Rev Anticancer Ther. 2010;10(11): 1811-1823.
Articles in this issue

Managing Toxicities in Melanoma
Managing Toxicities in Melanoma
Risk Factors and Trends in Melanoma
Risk Factors and Trends in Melanoma
Targeted Treatments for Melanoma
Targeted Treatments for Melanoma
Clinical Trials of Note
Clinical Trials of Note

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

Skin Cancer Awareness Month: Addressing Misconceptions and Promoting Prevention

Skin Cancer Awareness Month: Addressing Misconceptions and Promoting Prevention

Sabrina Serani
May 22nd 2025
Article

Michael E. Kasper, MD, FACRO, discussed unmet needs in skin cancer treatment and addressed misconceptions among patients and health care providers.

Read More


Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Jordyn Sava;Omid Hamid, MD
July 15th 2024
Podcast

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Listen


Roundtable Roundup: Early CAR T-cell Therapy in Multiple Myeloma

Roundtable Roundup: Early CAR T-cell Therapy in Multiple Myeloma

Targeted Oncology Staff
May 19th 2025
Article

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor (CAR) T-cell therapy.

Read More


Understanding and Treating Mucosal Melanoma

Understanding and Treating Mucosal Melanoma

Nichole Tucker;Richard Carvajal, MD
April 14th 2023
Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen


Melphalan/HDS Shows Benefit in Metastatic Uveal Melanoma

Melphalan/HDS Shows Benefit in Metastatic Uveal Melanoma

Jordyn Sava
May 17th 2025
Article

Melphalan/hepatic delivery system showed better survival and response rates than best alternative care in metastatic uveal melanoma in the FOCUS trial.

Read More


MR-LINAC Provides Greater Precision  With Adaptive Radiation Across Cancers

MR-LINAC Provides Greater Precision With Adaptive Radiation Across Cancers

Morgan Bayer
May 17th 2025
Article

Paul B. Renz, DO, discussed the ideal uses of MR-LINAC in pancreatic, prostate, liver, head and neck, and rectal cancers.

Read More

Related Content

Skin Cancer Awareness Month: Addressing Misconceptions and Promoting Prevention

Skin Cancer Awareness Month: Addressing Misconceptions and Promoting Prevention

Sabrina Serani
May 22nd 2025
Article

Michael E. Kasper, MD, FACRO, discussed unmet needs in skin cancer treatment and addressed misconceptions among patients and health care providers.

Read More


Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Jordyn Sava;Omid Hamid, MD
July 15th 2024
Podcast

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Listen


Roundtable Roundup: Early CAR T-cell Therapy in Multiple Myeloma

Roundtable Roundup: Early CAR T-cell Therapy in Multiple Myeloma

Targeted Oncology Staff
May 19th 2025
Article

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor (CAR) T-cell therapy.

Read More


Understanding and Treating Mucosal Melanoma

Understanding and Treating Mucosal Melanoma

Nichole Tucker;Richard Carvajal, MD
April 14th 2023
Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen


Melphalan/HDS Shows Benefit in Metastatic Uveal Melanoma

Melphalan/HDS Shows Benefit in Metastatic Uveal Melanoma

Jordyn Sava
May 17th 2025
Article

Melphalan/hepatic delivery system showed better survival and response rates than best alternative care in metastatic uveal melanoma in the FOCUS trial.

Read More


MR-LINAC Provides Greater Precision  With Adaptive Radiation Across Cancers

MR-LINAC Provides Greater Precision With Adaptive Radiation Across Cancers

Morgan Bayer
May 17th 2025
Article

Paul B. Renz, DO, discussed the ideal uses of MR-LINAC in pancreatic, prostate, liver, head and neck, and rectal cancers.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.